Cytomedix Announces AutoloGel System Poster Presentation at Wound Ostomy and Continence Nurses Society Conference

Cytomedix Announces AutoloGel System Poster Presentations at the Wound Ostomy and Continence Nurses Society Conference

Rockville, MD, . (June 15, 2010) – Cytomedix, Inc. (AMEX: GTF) a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that two posters highlighting the use of the Company’s AutoloGel™ System to effect rapid improvement of chronic wounds were presented at the 2010 Joint Conference of the Wound Ostomy and Continence Nurses Society and the World Council of Enterostomal Therapists (WOCN/WCET), taking place June 12-16, in Phoenix, Arizona.

The AutoloGel System is a device for the production of autologous platelet rich plasma (“PRP”) gel, and is the only PRP device cleared by the U.S. Food and Drug Administration (“FDA”) for wound management and use on a variety of exuding wounds. Its patent-protected formulation provides physiologically relevant concentrations of PRP that have proven clinically optimal for wound management and are well supported within the scientific literature.

The WOCN/WCET Poster Session with presenters is being held Tuesday, June 15, 2010 from 7:30 a.m. to 9:00 a.m. local time. Posters can be viewed throughout the conference and will close Wednesday, June 16 at 12:00 noon local time. The following posters highlighting Cytomedix’s PRP technology were presented at WOCN/WCET:

Commenting on the presentations, Martin P. Rosendale, President and CEO of Cytomedix, Inc., said, “An increasing body of clinical data demonstrates how the AutoloGel System’s physiologically relevant concentrations of PRP can rapidly restart the healing process in complex, non-healing wounds, including wounds that were recalcitrant to other treatments. We are delighted to bring new data to attendees at the WOCN/WCET Joint Conference.”

Founded in 1968, the Wound, Ostomy and Continence Nurses Society (WOCN) is a professional, international nursing society of more than 4,600 healthcare professionals who are experts in the care of patients with wound, ostomy and incontinence.

The World Council of Enterostomal Therapists (WCET) was inaugurated three decades ago in response to advances in nursing, medicine and surgery. These same developments also led to the creation of a new nursing specialty, Enterostomal Therapy Nursing (ETN), which has evolved over the past 30 years to become a major component in the management of ostomy, wound and continence care.

Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, to primarily address the areas of wound care, inflammation, and angiogenesis. The Company currently markets the AutoloGel™ System, a device for the production of platelet rich plasma (“PRP”) gel derived from the patient’s own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma (“PRP”) in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from platelet poor plasma. The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its products. Cytomedix is also pursuing opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics, as well as actively seeking complementary products for the wound care market. The Company also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing, or sale. Additional information regarding Cytomedix is available at www.cytomedix.com.

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix’s actual results may differ materially due to a number of factors, many of which are beyond Cytomedix’s ability to predict or control, including among others, viability and effectiveness of the Company’s sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, its ability to successfully commercialize its product in Japan under the terms of the license agreement, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.